Extended NICE drug-eluting stent consultation comes to an end:
This article was originally published in Clinica
Executive Summary
Next week sees the end of the extended consultation by the UK's National Institute for Health and Clinical Excellence (NICE) on NHS use of drug-eluting stents (DESs) to treat coronary artery disease. After allowing an extra month - to October 1 - for commenting on economic modelling data added to the consultation documentation on August 30 (two days after the original August 28 deadline - see Clinica No 1272, p 7), NICE's first appraisal committee meeting is now due to be held in November. Subject to any appeals process, the final guidance is scheduled for publication in March 2008.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.